Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer

Summary

RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of kidney cancer by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying the side effects and how well bevacizumab works in treating patients with unresectable or metastatic kidney cancer.

Timeline

Start

2008-02

Primary completion

2011-08

Completion

2013-05

Outcome

Outcome not reported

Stopped (Enrollment): “Poor patient accrual. Attempts to open at other sites unsuccessful.”

Drugs

Indications